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Background & Aims: Recently, single nucleotide polymorphisms (SNPs) in IL28B were shown to correlate with response 
to pegylated interferon-a (IFN) and ribavirin therapy of chronic HCV infection. However, the cause for the SNPs effect on 
therapy response and its application for direct anti-viral (DAV) treatment are not clear. Here, we analyze early HCV 
kinetics as function of IL28B SNPs to determine its specific effect on viral dynamics. 
Methods: IL28B SNPs rs8099917, rs12979860 and rs12980275 were genotyped in 252 chronically HCV infected 
Caucasian naïve patients (67% HCV genotype 1, 28% genotype 2-3) receiving peginterferon-alfa-2a (180 µg/qw) plus 
ribavirin (1000-1200 mg/qd) in the DITTO study. HCV-RNA was measured (LD=50 IU/ml) frequently during first 28 days.  
Results: RVR was achieved in 33% of genotype 1 patients with genotype CC at rs12979860 versus 12-16% for 
genotypes TT and CT (P< 0.03). Significant (P< 0.001) difference in viral decline was observed already at day 1 (see 
Figure). First phase decline was significantly (P< 0.001) larger in patients with genotype CC (2.0 log) than for TT and CT 
genotypes (0.6 and 0.8), indicating IFN anti-viral effectiveness in blocking virion production of 99% versus 75-84%. 
There was no significant association between second phase slope and rs12979860 genotype in patients with a first phase 
decline larger than 1 log. 
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The same trend (not shown) was observed for HCV genotype 2-3 patients with different SNP genotype distribution that 
may indicate differential selection pressure as function of HCV genotype. 
Similar results were observed for SNPs rs8099917 and rs12980275, with a strong linkage disequilibrium among the 3 loci 
allowing to define the composite haplotype best associated with IFN effectiveness. 
Conclusions: IFN effectiveness in blocking virion production/release is strongly affected by IL28B SNPs, but not other 
viral dynamic properties such as infected cell loss rate. Thus, IFN based therapy, as standard-of-care or in combination 
with DAV, should consider IL28B SNPs for prediction and personalized treatment, while response to pure DAV treatment 
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